Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics

Abstract Heat shock protein 90 (HSP90) inhibition is an attractive strategy for cancer treatment. Several HSP90 inhibitors have shown promising effects in clinical oncology trials. However, little is known about HSP90 inhibition-mediated bladder cancer therapy. Here, we report a quantitative proteom...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Qingdi Quentin Li, Jian-Jiang Hao, Zheng Zhang, L. Spencer Krane, Kai H. Hammerich, Thomas Sanford, Jane B. Trepel, Len Neckers, Piyush K. Agarwal
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/d315dc00c8384dfc8ae699ecec61f833
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d315dc00c8384dfc8ae699ecec61f833
record_format dspace
spelling oai:doaj.org-article:d315dc00c8384dfc8ae699ecec61f8332021-12-02T16:07:02ZProteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics10.1038/s41598-017-00143-62045-2322https://doaj.org/article/d315dc00c8384dfc8ae699ecec61f8332017-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-00143-6https://doaj.org/toc/2045-2322Abstract Heat shock protein 90 (HSP90) inhibition is an attractive strategy for cancer treatment. Several HSP90 inhibitors have shown promising effects in clinical oncology trials. However, little is known about HSP90 inhibition-mediated bladder cancer therapy. Here, we report a quantitative proteomic study that evaluates alterations in protein expression and histone post-translational modifications (PTMs) in bladder carcinoma in response to HSP90 inhibition. We show that 5 HSP90 inhibitors (AUY922, ganetespib, SNX2112, AT13387, and CUDC305) potently inhibited the proliferation of bladder cancer 5637 cells in a dose- and time-dependent manner. Our proteomic study quantified 518 twofold up-regulated and 811 twofold down-regulated proteins common to both AUY922 and ganetespib treatment. Bioinformatic analyses revealed that those differentially expressed proteins were involved in multiple cellular processes and enzyme-regulated signaling pathways, including chromatin modifications and cell death-associated pathways. Furthermore, quantitative proteome studies identified 14 types of PTMs with 93 marks on the core histones, including 34 novel histone marks of butyrylation, citrullination, 2-hydroxyisobutyrylation, methylation, O-GlcNAcylation, propionylation, and succinylation in AUY922- and ganetespib-treated 5637 cells. Together, this study outlines the association between proteomic changes and histone PTMs in response to HSP90 inhibitor treatment in bladder carcinoma cells, and thus intensifies the understanding of HSP90 inhibition-mediated bladder cancer therapeutics.Qingdi Quentin LiJian-Jiang HaoZheng ZhangL. Spencer KraneKai H. HammerichThomas SanfordJane B. TrepelLen NeckersPiyush K. AgarwalNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-20 (2017)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Qingdi Quentin Li
Jian-Jiang Hao
Zheng Zhang
L. Spencer Krane
Kai H. Hammerich
Thomas Sanford
Jane B. Trepel
Len Neckers
Piyush K. Agarwal
Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics
description Abstract Heat shock protein 90 (HSP90) inhibition is an attractive strategy for cancer treatment. Several HSP90 inhibitors have shown promising effects in clinical oncology trials. However, little is known about HSP90 inhibition-mediated bladder cancer therapy. Here, we report a quantitative proteomic study that evaluates alterations in protein expression and histone post-translational modifications (PTMs) in bladder carcinoma in response to HSP90 inhibition. We show that 5 HSP90 inhibitors (AUY922, ganetespib, SNX2112, AT13387, and CUDC305) potently inhibited the proliferation of bladder cancer 5637 cells in a dose- and time-dependent manner. Our proteomic study quantified 518 twofold up-regulated and 811 twofold down-regulated proteins common to both AUY922 and ganetespib treatment. Bioinformatic analyses revealed that those differentially expressed proteins were involved in multiple cellular processes and enzyme-regulated signaling pathways, including chromatin modifications and cell death-associated pathways. Furthermore, quantitative proteome studies identified 14 types of PTMs with 93 marks on the core histones, including 34 novel histone marks of butyrylation, citrullination, 2-hydroxyisobutyrylation, methylation, O-GlcNAcylation, propionylation, and succinylation in AUY922- and ganetespib-treated 5637 cells. Together, this study outlines the association between proteomic changes and histone PTMs in response to HSP90 inhibitor treatment in bladder carcinoma cells, and thus intensifies the understanding of HSP90 inhibition-mediated bladder cancer therapeutics.
format article
author Qingdi Quentin Li
Jian-Jiang Hao
Zheng Zhang
L. Spencer Krane
Kai H. Hammerich
Thomas Sanford
Jane B. Trepel
Len Neckers
Piyush K. Agarwal
author_facet Qingdi Quentin Li
Jian-Jiang Hao
Zheng Zhang
L. Spencer Krane
Kai H. Hammerich
Thomas Sanford
Jane B. Trepel
Len Neckers
Piyush K. Agarwal
author_sort Qingdi Quentin Li
title Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics
title_short Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics
title_full Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics
title_fullStr Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics
title_full_unstemmed Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics
title_sort proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics
publisher Nature Portfolio
publishDate 2017
url https://doaj.org/article/d315dc00c8384dfc8ae699ecec61f833
work_keys_str_mv AT qingdiquentinli proteomicanalysisofproteomeandhistoneposttranslationalmodificationsinheatshockprotein90inhibitionmediatedbladdercancertherapeutics
AT jianjianghao proteomicanalysisofproteomeandhistoneposttranslationalmodificationsinheatshockprotein90inhibitionmediatedbladdercancertherapeutics
AT zhengzhang proteomicanalysisofproteomeandhistoneposttranslationalmodificationsinheatshockprotein90inhibitionmediatedbladdercancertherapeutics
AT lspencerkrane proteomicanalysisofproteomeandhistoneposttranslationalmodificationsinheatshockprotein90inhibitionmediatedbladdercancertherapeutics
AT kaihhammerich proteomicanalysisofproteomeandhistoneposttranslationalmodificationsinheatshockprotein90inhibitionmediatedbladdercancertherapeutics
AT thomassanford proteomicanalysisofproteomeandhistoneposttranslationalmodificationsinheatshockprotein90inhibitionmediatedbladdercancertherapeutics
AT janebtrepel proteomicanalysisofproteomeandhistoneposttranslationalmodificationsinheatshockprotein90inhibitionmediatedbladdercancertherapeutics
AT lenneckers proteomicanalysisofproteomeandhistoneposttranslationalmodificationsinheatshockprotein90inhibitionmediatedbladdercancertherapeutics
AT piyushkagarwal proteomicanalysisofproteomeandhistoneposttranslationalmodificationsinheatshockprotein90inhibitionmediatedbladdercancertherapeutics
_version_ 1718384808211513344